Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia

Lignende værker

• Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
  af: Othman Al-Sawaf, et al.
  Udgivet: (2023-10-01)
• S148: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 5-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
  af: O. Al-Sawaf, et al.
  Udgivet: (2022-06-01)
• S143: TRANSCRIPTOMIC CHARACTERIZATION OF MRD RESPONSE AND NON-RESPONSE IN PATIENTS TREATED WITH FIXED-DURATION VENETOCLAX-OBINUTUZUMAB
  af: O. Al-Sawaf, et al.
  Udgivet: (2022-06-01)
• Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients
  af: Paul J. Hengeveld, et al.
  Udgivet: (2025-01-01)
• S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
  af: Othman Al-Sawaf, et al.
  Udgivet: (2023-08-01)